close

Enter

Log in using OpenID

Novel Drugs and Devices to Lower Intraocular Pressure Market To Register Unwavering Growth During in Global by 2026

embed
Intraocular pressure is the pressure present inside the eye. The aqueous humour of the ciliary body in the eye is responsible for the intraocular pressure. The production and removal rate of aqueous humour by the ciliary body determines the pressure
Novel Drugs and Devices to Lower Intraocular
Pressure Market To Register Unwavering Growth
During in Global by 2027
Novel Drugs and Devices to Lower Intraocular Pressure Market, by Treatment
Type (Drug (Rhopressa, Roclatan, Xelpros, Vyzulta and Others) and Device
(Implant, Therapeutic Ultrasound and Others), by Distribution Channel
(Hospitals & Clinics, Retail Channel and Online Channels), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size,
Share, Outlook, and Opportunity Analysis, 2019 – 2027
Intraocular pressure is the pressure present inside the eye. The aqueous humour of the ciliary body in
the eye is responsible for the intraocular pressure. The production and removal rate of aqueous humour
by the ciliary body determines the pressure in the eye. The presence of extra fluid (aqueous humour)
builds up pressure in the eye which can lead to glaucoma. There are two types of glaucoma, open–
angle glaucoma and closed–angle glaucoma. Generally, tonometers are used for determining the
pressure present in the eye. Click To Read More On Novel Drugs and Devices to Lower Intraocular
Pressure Market.
Global Novel Drugs and Devices to Lower Intraocular Pressure Market Drivers
Approvals of drugs and devices associated with the treatment of glaucoma from regulatory bodies is
expected to boost the global novel drugs and devices to lower intraocular pressure market growth. For
instance, in May 2019, Ivantis Inc., received an approval from the U.S. Food and Drug Administration
(FDA) for Hydrus microstent. It is a device used in minimally invasive glaucoma surgery. It is
developed to lower eye pressure in patients with open angle glaucoma.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/2670
Furthermore, in September 2018, Sun Pharmaceuticals Industries Ltd. received an approval from U.S.
FDA for Xelpros (latanoprost ophthalmic emulsion) for treatment of glaucoma. It reduces the elevated
intraocular pressure in the eye and has been designed with the help of Swollen Micelle Micro emulsion
technology. Frequent approvals of drugs and devices is expected to accelerate global novel drugs and
devices to lower intraocular pressure market growth.
Global Novel Drugs and Devices to Lower Intraocular Pressure Market Key Players
Some of the major players operating in the global novel drugs and devices to lower intraocular pressure
market include, Mati Therapeutics Inc, BioLight Lifesciences Ltd., IOPtima Ltd., Eye Sonix, Bausch &
Lomb Inc., Sun Pharmaceutical Industries Ltd., Allergan, Alcon Inc., Glaukos Corporation, and Pfizer
Inc.
Global Novel Drugs and Devices to Lower Intraocular Pressure Market Regional Analysis
North America is expected to be dominant in global novel drugs and devices to lower intraocular
pressure market during the forecast period. Factors such as government initiatives expected to augment
the North America novel drugs and devices to lower intraocular pressure market growth. For instance,
in January 2019, Glaucoma Research Foundation, U.S., formed a team called Catalyst for a Cure. The
investigators are working together to understand the exact cause of vision loss in glaucoma patients,
and potential targeted therapies for the prevention and treatment of glaucoma. As a result, this factor is
expected to support the global novel drugs and devices to lower intraocular pressure market growth.
Key players are focused on monitoring post marketing results of approved drugs and devices for the
treatment of glaucoma (Intraocular pressure), which is expected to drive the global novel drugs and
devices to lower intraocular pressure market growth.
Rhopressa drug manufactured by Aerie Pharmaceuticals was originally approved in December 2017 by
U.S. Food and Drug Administration (FDA). The company is now studying the Rhopressa drug
(Netarsudil ophthalmic solution) for its pharmacovigilance studies. The drug is being studied for its
long-term effects on patients with open angle glaucoma and ocular hypertension. The study is expected
to be completed by September 2019. Such developments are expected to drive the global novel drugs
and devices to lower intraocular pressure market growth.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran301   document Email
Document
Category
Health and Medicine
Views
3
File Size
368 KB
Tags
pressure
1/--pages
Report inappropriate content